Please assess the completion status of the following clinical trial:

Trial Title: Transcranial Electrical Stimulation for mTBI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion of Veterans for the mTBI groups:~* All symptomatic mTBI patients will be evaluated in a clinical interview to document the nature of the injuries and ongoing PCS.~* The diagnosis of mTBI patients is based on standard VA/DOD diagnostic criteria.~* Inclusion in the mTBI patient group requires a TBI that meets the following criteria:~  * a loss of consciousness (LOC) \< 30 minutes or transient confusion, disorientation, or impaired consciousness immediately after the trauma~ * post-traumatic amnesia (PTA) \< 24 hours~ * an initial Glasgow Coma Scale (GCS) \[90\] between 13-15 (if available)~* Since the GCS assessment is often not available in theater, Veterans with missing GCS, but who meet other inclusion criteria will also be recruited.~* Each patient must have at least 3 items of persistent PCS at the beginning of the study.~Inclusion of Healthy Control (HC) group:~* Veterans that qualify as HCs will be age, education, combat exposure, and socioeconomically matched to the mTBI groups.~* In addition to exclusion criteria listed above, HC subjects must not have been diagnosed with head injury, affective disorder, or PTSD (CAPS-5 \< 8) throughout life.~Exclusion Criteria:~* Exclusion criteria for study participations include:~* history of other neurological, developmental, or psychiatric disorders (based on the DSM-5 (MINI-7) \[86\] structured interview), e.g.,:~  * brain tumor~ * stroke~ * epilepsy~ * Alzheimer's disease~ * schizophrenia~ * bipolar disorder~ * ADHD~ * or other chronic neurovascular diseases such as hypertension and diabetes~* substance or alcohol use disorders according to DSM-5 \[87\] criteria within the six months prior to the study~* history of metabolic or other diseases known to affect the central nervous system (see \[88\] for similar criteria)~* Metal objects (e.g., shrapnel or metal fragments) that fail MRI screening, or extensive metal dental hardware, e.g.,:~  * braces and large metal dentures~    * fillings are acceptable~ * other metal objects in the head~ * neck, or face areas that cause non-removable artifacts in the MEG data~* Potential subjects will be administered the Beck Depression Inventory (BDI-II) to evaluate level of depressive symptoms, and suicidal ideation~  * any participant who reports a 2 or 3 on the BDI-II: item 9 (suicidal thoughts or wishes) will also be excluded.~ * However, depression following mTBI or traumatic event of PTSD is common \[89\]: therefore, in two mTBI groups, the investigators will include and match patients with depression symptoms reported after their injury/event, and will co-vary BDI-II score in data analyses.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Transcranial Electrical Stimulation (TES) (Type: EXPERIMENTAL): mTBI Veterans blindly assigned to a 6 week of TES, either IASIS neurofeedback treatment or Nexalin, with 2-3 sessions per week.
- Sham Treatment (Type: PLACEBO_COMPARATOR): mTBI Veterans blindly assigned to a sham treatment for 6 weeks with 2-3 sessions per week.
- Control (Type: NO_INTERVENTION): Veterans who are age-, gender-, education-, combat exposure-, and socioeconomically-matched. They will not undergo a treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete